MINOR INDEPENDENT CLONES IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA HAVE A CLL-BIASED BIOLOGICAL SIGNATURE: IMPLICATIONS FOR DISEASE ONTOGENY AND EVOLUTION

EHA Library, Ian Márquez-López, 4159181

BLOOD-BASED PROTEOMICS FOR DEEPER INSIGHTS INTO INDOLENT SYSTEMIC MASTOCYTOSIS: THE PIONEER TRIAL EXPERIENCE

EHA Library, Yu-An Kuo, 4171792

EVALUATION OF GONADAL FUNCTION IN FEMALE PATIENTS WITH HODGKIN LYMPHOMA (HL) AND PRIMARY MEDIASTINAL B-CELL LYMPHOMA (PMBCL) UNDERGOING CHEMOTHERAPY

EHA Library, Angeliki Georgopoulou, 4160283

EFFICACY AND SAFETY OF FIRST-LINE IBRUTINIB PLUS VENETOCLAX IN PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO WERE OLDER OR HAD TP53 MUTATIONS IN THE SYMPATICO STUDY

EHA Library, Gottfried von Keudell, 4160284

TQB2825, A NOVEL 2:1 STRUCTURED CD20XCD3 BISPECIFIC ANTIBODY,IN THE RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA

EHA Library, Keshu Zhou, 4160285

CAN MANTLE CELL LYMPHOMA BE CURED? INSIGHTS FROM 25 YEARS OF FOLLOW-UP IN THE NORDIC MCL2 AND MCL3 TRIALS

EHA Library, Mats Jerkeman, 4160286

EPCORITAMAB MONOTHERAPY DEMONSTRATES DEEP AND DURABLE RESPONSES AT 3-YEAR FOLLOW-UP IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA

EHA Library, Umberto Vitolo, 4160287

MOSUNETUZUMAB DEMONSTRATES DURABLE CLINICAL BENEFIT IN PATIENTS (PTS) WITH COMPLETE RESPONSE (CR) AND HIGH-RISK RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)

EHA Library, Chan Cheah, 4160289

UPDATED SAFETY AND EFFICACY RESULTS OF A PHASE 1 STUDY OF THE NOVEL BCL2 INHIBITOR SONROTOCLAX (BGB-11417) FOR RELAPSED/REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA

EHA Library, Chan Y. Cheah, 4160293

EFFICACY AND SAFETY OF NEMTABRUTINIB IN RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA: UPDATED ANALYSIS OF COHORT F OF THE PHASE 2 BELLWAVE-003 STUDY

EHA Library, Alessandra Tucci, 4160294

REAL WORLD EXPERIENCE FINDS NO DIFFERENCE IN TIME TO 2ND LINE TREATMENT BETWEEN OBINUTUZUMAB AND RITUXIMAB-CONTAINING REGIMENS AMONG PATIENTS WITH FOLLICULAR LYMPHOMA

EHA Library, Dor Shpitzer, 4160299

IMPACT OF TP53 MUTATION STATUS ON OUTCOMES AFTER FIRST-LINE TREATMENT IN LYMPHOPLASMACYTIC LYMPHOMA.

EHA Library, Sherif Seif, 4160301

ORELABRUTINIB COMBINED WITH BENDAMUSTINE-RITUXIMAB OR OBINUTUZUMAB FOLLOWED BY ORELABRUTINIB MAINTENANCE IN UNTREATED MARGINAL ZONE LYMPHOMA (OPTIMIZE): A MULTICENTER, SINGLE-ARM, PHASE II STUDY

EHA Library, Wenjuan Yu, 4160304

MATCHING-ADJUSTED INDIRECT COMPARISON OF LISOCABTAGENE MARALEUCEL VERSUS AXICABTAGENE CILOLEUCEL AND TISAGENLECLEUCEL FOR TREATMENT OF THIRD-LINE OR LATER R/R FL: UPDATE WITH 24 MONTHS OF FOLLOW-UP

EHA Library, Alexander P. Boardman, 4160306

RARE LYMPHOID MALIGNANCIES; EPIDEMIOLOGICAL CHARACTERISTICS AT THE POPULATION LEVEL

EHA Library, Marc Maynadié, 4160310

IMPACT OF BASELINE SUVMAX IN UNTREATED HIGH-TUMOR-BURDEN FOLLICULAR LYMPHOMA

EHA Library, Ikram Bouguern, 4160312

REAL-WORLD EVIDENCE ON MOGAMULIZUMAB FOR SÉZARY SYNDROME AND MYCOSIS FUNGOIDES IN PATIENTS AGED 75 AND OLDER.

EHA Library, Erika Morsia, 4160313

A PHASE 2 STUDY OF TAZEMETOSTAT (TAZ) IN CHINESE PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) HARBORING ENHANCER-OF-ZESTE-HOMOLOG-2 MUTATIONS (EZH2MUT)

EHA Library, Junning Cao, 4160316

THE PROGNOSTIC ROLE OF NEUTROPHIL-TO-LYMPHOCYTE RATIO (NLR) IN WALDENSTRÖM MACROGLOBULINEMIA: AN INDEPENDENT PROGNOSTIC MARKER

EHA Library, David Kaldas, 4160317

THE REAL-WORLD EFFICACY AND SAFETY OF OBINUTUZUMAB-BASED INDUCTION THERAPY FOR UNTREATED FOLLICULAR LYMPHOMA: A SINGLE-CENTER RETROSPECTIVE ANALYSIS

EHA Library, Fangfang LYU, 4160319

REAL-WORLD ZANUBRUTINIB TREATMENT PATTERNS IN MANTLE CELL LYMPHOMA AMONG US COMMUNITY ONCOLOGY PATIENTS WITH PRIOR BRUTON TYROSINE KINASE INHIBITOR THERAPY

EHA Library, Rushir Choksi, 4160320

MINIMAL RESIDUAL DISEASE-GUIDED THERAPY WITH ORELABRUTINIB AND RITUXIMAB IN TREATMENT-NAÏVE MARGINAL ZONE LYMPHOMA

EHA Library, Wenzhe Yan, 4160321

PET GUIDED OMISSION OF RADIOTHERAPY IN ELDERLY DLBCL PATIENTS WITH LESS FAVOURABLE PROGNOSIS IS SAFE: RESULTS OF 863 PATIENTS TREATED IN THE OPTIMAL>60 TRIAL OF THE DSHNHL/GLA

EHA Library, Viola Pöschel, 4160323

POLATUZUMAB VEDOTIN, RITUXIMAB, AND LENALIDOMIDE (POLA-R2) AS FIRST-LINE THERAPY FOR UNFIT AND FRAIL ELDERLY DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: PRELIMINARY RESULTS FROM A PROSPECTIVE, PHASE II, MULTI-CENTER STUDY

EHA Library, Wei Wang, 4160327

NOVEL ZCR (ZANUBRUTINIB, CHIDAMIDE, RITUXIMAB) ± CHOP REGIMEN DEMONSTRATES PROMISING EFFICACY IN FRONTLINE TREATMENT OF DOUBLE-EXPRESSOR DIFFUSE LARGE B-CELL LYMPHOMA(DE-DLBCL)

EHA Library, Zhi-Ming Li, 4160328

ANTI-CD19 CAR-T CELL THERAPY IN RELAPSED/REFRACTORY T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA (THRLBCL): INSIGHTS FROM THE FRENCH DESCAR-T REGISTRY, A LYSA STUDY.

EHA Library, Axel Andre, 4160331

IBRUTINIB DOSE MODIFICATION IN MANTLE CELL LYMPHOMA: AN ITALIAN REAL-LIFE MULTICENTER EXPERIENCE. RESULTS FROM THE REDOT_MCL STUDY.

EHA Library, Luca Pagliaro, 4160332

ZANUBRUTINIB AND RITUXIMAB REGIMEN COMBINED WITH INTRAVITREAL METHOTREXATE FOR PRIMARY VITREORETINAL LYMPHOMA: A PHASE II STUDY

EHA Library, Zhe Zhuang, 4160333

THE IMPACT OF SOCIOECONOMIC STATUS ON SURVIVAL OF PATIENTS WITH LARGE B-CELL LYMPHOMA IN FINLAND, A POPULATION-BASED ANALYSIS

EHA Library, Joonas Kuitunen, 4160334

MOLECULAR FEATURES ENCODED IN THE DYNAMIC CTDNA MONITORING REVEAL ADDITIONALLY PROGNOSTIC VALUE, DIFFERENT CLINICAL COURSES AND CLONE EVOLUTION FOR DIFFERENT GENETIC SUBTYPES OF DIFFUSE LARGE B CELL LYMPHOMA

EHA Library, Jinhua Liang, 4160335

SUPERIOR OUTCOMES OF AUTOLOGOUS TRANSPLANTATION VERSUS CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN RELAPSED CNS LYMPHOMA TREATED IN COMPLETE REMISSION

EHA Library, Yuelu Guo, 4160339

BMS-986458, A FIRST-IN-CLASS, BIFUNCTIONAL CEREBLON-DEPENDENT LIGAND-DIRECTED DEGRADER (LDD) OF B-CELL LYMPHOMA 6 (BCL6) IN PATIENTS WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA: INITIAL PH 1 RESULTS

EHA Library, Franck Morschhauser, 4160340

ZANUBRUTINIB IN COMBINATION WITH R-MTX FOR NEWLY DIAGNOSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

EHA Library, Xibin Xiao, 4160341

INCIDENCE AND SURVIVAL OF PRIMARY CNS LYMPHOMA: AN ENGLAND-WIDE COHORT STUDY FROM THE UNCOVER STUDY GROUP

EHA Library, Sarrah Tayabali, 4160343

SAFETY AND EFFICACY OF DUAL-TARGET CD19/CD20 CAR-T THERAPY IN RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA

EHA Library, Liu Rui, 4160344

BISPECIFIC ANTIBODIES AS HOLDING OR BRIDGING THERAPY BEFORE CAR-T IN LARGE B-CELL LYMPHOMA

EHA Library, Hanna Katharina Zieger, 4160350

THE RESULT OF A SINGLE-ARM, PHASE IB, MULTI-CENTER STUDY OF RITUXIMAB, ACALABRUTINIB, AND DURVALUMAB (RAD) IN THE RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)

EHA Library, Kwang-Yu Chang, 4160351

POMALIDOMIDE, RITUXIMAB, ORELABRUTINIB, AND MINICHOP-LIKE (PRO-MINICHOP) IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA: UPDATED RESULTS FROM A PHASE II STUDY

EHA Library, Na-Na Ping, 4160356

EPIDEMIOLOGICAL AND SURVIVAL TRENDS OF ALK-POSITIVE LARGE B-CELL LYMPHOMA: A SEER (SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS) STUDY

EHA Library, Jeyapradeeban Arunachalam, 4160357

CONTROLLING NUTRITIONAL STATUS (CONUT) SCORE AS A PROGNOSTIC FACTOR FOR SURVIVAL IN CAR-T THERAPY FOR RELAPSED/REFRACTORY B-CELL LYMPHOMA

EHA Library, Yuelu Guo, 4160358

REAL-WORLD OUTCOMES OF POLA-RB (POLATUZUMAB VEDOTIN, RITUXIMAB, BENDAMUSTINE) IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: INSIGHTS FROM THE POLISH LYMPHOMA RESEARCH GROUP

EHA Library, Magdalena Olszewska-Szopa, 4160362

CYTOKINE RELEASE SYNDROME (CRS) AND IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME (ICANS) IN LYMPHOMA PATIENTS RECEIVING AXICABTAGENE CILOLEUCEL: ANALYSIS BY YEAR OF TREATMENT AND INDICATIONS

EHA Library, Anna Dodero, 4160363

VALIDATION OF ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL) SCORE IN KOREAN AITL PATIENTS

EHA Library, bohyun moon, 4160366

ROBUST SINGLE AGENT ACTIVITY OF BI-1808, A TUMOR NECROSIS FACTOR RECEPTOR 2 (TNFR2) BLOCKER/DEPLETER, IN CUTANEOUS T CELL LYMPHOMA (CTCL) PATIENTS

EHA Library, Stefan Barta, 4160367

COMBINATION OF MITOXANTRONE HYDROCHLORIDE LIPOSOME WITH GEMCITABINE, CISPLATIN AND DEXAMETHASONE (MGDP) IN PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T CELL LYMPHOMA: A PROSPECTIVE, SINGLE-ARM, MULTICENTER, PHASE I/II STUDY

EHA Library, Chong Wei, 4160369

CLINICOPATHOLOGIC FEATURES AND SURVIVAL OUTCOMES OF POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE BY LIVER TRANSPLANT DONOR GRAFT TYPE

EHA Library, Seong-Eun Kim, 4160370

PROPENSITY SCORE-MATCHED ANALYSIS SUPPORTS THE SURVIVAL BENEFITS OF CAR-T THERAPY WITH TANDEM STEM CELL SUPPORT IN NHL: INSIGHTS FROM A REAL-WORLD STUDY IN CHINA

EHA Library, Haiwen Huang, 4160371

A SINGLE-CENTER RETROSPECTIVE ANALYSIS OF CLINICAL CHARACTERISTICS AND TREATMENT OUTCOMES IN 104 NEWLY DIAGNOSED ENKTL PATIENTS

EHA Library, Haiwen Huang, 4160373

LORLATINIB THERAPY IN RELAPSED/REFRACTORY ALK + LYMPHOMAS PREVIOUSLY TREATED WITH TYROSINE KINASE INHIBITORS

EHA Library, Carlo Gambacorti-Passerini, 4160378

KMT2A MUTATIONS CONFER ADVERSE PROGNOSIS IN PERIPHERAL T-CELL LYMPHOMA: A SINGLE-CENTER RETROSPECTIVE STUDY

EHA Library, Youngwoo Jeon, 4160379

MECHANISMS OF FIBROCYTE INDUCTION IN LYMPHOID MALIGNANCIES: THE ROLE OF CCL22 AND TIMP-1 IN SECONDARY MYELOFIBROSIS

EHA Library, Noriaki Tachi, 4160231

MINIMAL RESIDUAL DISEASE WITH BENDAMUSTINE-RITUXIMAB WITH OR WITHOUT ACALABRUTINIB IN PATIENTS WITH PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA: RESULTS FROM THE PHASE 3 ECHO TRIAL

EHA Library, Michael L. Wang, 4160288

IMPACT OF RITUXIMAB MAINTENANCE ON SURVIVAL AMONG PATIENTS WITH MANTLE CELL LYMPHOMA; A POPULATION-BASED COHORT STUDY

EHA Library, Floriske Stedema, 4160290

EPCORITAMAB PLUS LENALIDOMIDE AND RITUXIMAB ACHIEVES HIGH RESPONSE RATES AND SURVIVAL BENEFITS COMPARED WITH USUAL CARE IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: A COMPARATIVE ANALYSIS

EHA Library, Lorenzo Falchi, 4160291

A PROSPECTIVE MULTICENTER PHASE 2 STUDY OF THE CHEMOTHERAPY-FREE COMBINATION OF THE INTRAVENOUS PHOSPHATIDYLINOSITOL-3-KINASE (PI3K) INHIBITOR COPANLISIB IN COMBINATION WITH OBINUTUZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (FL) AND A HIGH TUMOR BURDEN (ALTERNATIVE-C)

EHA Library, Christian Schmidt, 4160292

CLINICAL CHARACTERISTICS AND OUTCOMES OF INCIDENTAL VS SYMPTOMATIC FOLLICULAR LYMPHOMA

EHA Library, Suheil Albert Atallah-Yunes, 4160295

REAL-WORLD TREATMENT PATTERNS AND OUTCOMES IN HIGH-RISK, TREATMENT-NAIVE MANTLE CELL LYMPHOMA: A MULTINATIONAL ANALYSIS FROM THE UK, SWEDEN, AND FRANCE

EHA Library, Alexandra Smith, 4160296

FREE LIGHT CHAIN (FLC) RATIO IS AN INDEPENDENT PROGNOSTIC RISK FACTOR FOR PROGRESSION TO SYMPTOMATIC WALDENSTROM'S MACROGLOBULINEMIA

EHA Library, Gianmarco Favrin, 4160297

EZH2 MUTATION STATUS IS NOT PREDICTIVE IN R-CHOP AND R-B TREATED FOLLICULAR LYMPHOMA PATIENTS - A MULTICENTRIC COHORT STUDY AND META-ANALYSIS

EHA Library, Richárd Hanza, 4160298

RISK OF LYMPHOMA AND OTHER HAEMATOLOGIC MALIGNANCIES IN INCIDENTALLY DETECTED SPLENOMEGALY: PROSPECTIVE STUDY OF 47,066 CT/MR SCANNED GENERAL POPULATION INDIVIDUALS FROM DENMARK AND THE UNITED KINGDOM

EHA Library, Anne Rudbeck Juhl, 4160300

COMPARATIVE EFFECTIVENESS OF ODRONEXTAMAB VERSUS REAL-WORLD SYSTEMIC THERAPIES USED IN AN EXTERNAL CONTROL ARM IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA

EHA Library, Emmanuel Bachy, 4160302

CLINICAL CHARACTERISTICS AND MOLECULAR HETEROGENEITY IN FOLLICULAR LYMPHOMA WITH EXTRANODAL INVOLVEMENT

EHA Library, WeiLi Zhao, 4160303

REAL-WORLD BURDEN OF DISEASE, TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH MANTLE CELL LYMPHOMA (MCL)

EHA Library, Alvaro J. Alencar, 4160305

INCIDENCE AND SURVIVAL OUTCOMES OF PRIMARY PAROTID FOLLICULAR LYMPHOMA (PPFL): A SEER-BASED RETROSPECTIVE ANALYSIS

EHA Library, Jeyapradeeban Arunachalam, 4160307

FEATURES AND OUTCOMES OF ASYMPTOMATIC WALDENSTRÖM MACROGLOBULINEMIA IN RELATION TO BONE MARROW INFILTRATION: AN ITALIAN UNIVERSITY HOSPITAL ANALYSIS

EHA Library, Nicolò Danesin, 4160308

LONG-TERM RESULTS OF THE „MCL-2016” PROTOCOL IN PATIENTS WITH MANTLE CELL LYMPHOMA IN DIFFERENT PROGNOSTIC GROUPS

EHA Library, Daria Koroleva, 4160309

A PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY ON THE COMBINATION OF ORELABRUTINIB AND RITUXIMAB IN THE SECOND-LINE TREATMENT OF RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA

EHA Library, Lixia Sheng, 4160311

GOLIDOCITINIB MONOTHERAPY IN THE TREATMENT OF REFRACTORY/RELAPSED INDOLENT T/NK-CELL LYMPHOMA: PRELIMINARY RESULTS FROM T-LGLL COHORT

EHA Library, Ying Yu, 4160314

PROGRESSION-FREE SURVIVAL IMPROVEMENT OF LOCALIZED OCULAR ADNEXAL MALT LYMPHOMA PATIENTS WITH RESIDUAL LESIONS: COMPARATIVE OUTCOME OF POSTOPERATIVE TREATMENT VERSUS WATCHFUL WAITING

EHA Library, Jun Shi, 4160315

POSITRON EMISSION TOMOGRAPHY-ADAPTED THERAPY IN LOW-RISK DIFFUSE LARGE B-CELL LYMPHOMA: 4-YEAR RESULTS OF A RANDOMIZED, PHASE III, NON-INFERIORITY TRIAL

EHA Library, Qing Shi, 4160322

RELMACABTAGENE AUTOLEUCEL (RELMA-CEL) AS SECOND-LINE THERAPY FOR R/R AGGRESSIVE B-NHL IN PATIENTS INELIGIBLE FOR HDCT/ASCT: PRIMARY ANALYSIS FROM A PHASE 2 STUDY

EHA Library, Qingqing Cai, 4160324

PROMISING EFFICACY OF AT101, A NOVEL ANTI-CD19 CAR-T THERAPY, IN RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA: INTERIM ANALYSIS OF A MULTICENTER PHASE 2 TRIAL

EHA Library, Dok Hyun Yoon, 4160325

SUSTAINED REMISSION IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA WITH EPCORITAMAB MONOTHERAPY: EPCORE NHL-1 3-Y RESULTS AND NOVEL SUBGROUP ANALYSES IN PATIENTS WITH COMPLETE RESPONSE AT 2 Y

EHA Library, Chan Y. Cheah, 4160326

ZANUBRUTINIB IN COMBINATION WITH R-CHOP FOR PREVIOUSLY UNTREATED MCD TYPE OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

EHA Library, Wenjuan Yu, 4160329

THREE-HOUR INFUSION OF METHOTREXATE AT 3 G/M2 SIGNIFICANTLY REDUCES CNS RECURRENCES AND IMPROVES SURVIVAL IN LARGE B-CELL LYMPHOMAS WITH INCREASED CNS RISK: ANALYSIS OF A SINGLE-CENTER COHORT OF 501 PATIENTS

EHA Library, Andrés Ferreri, 4160330

FOLLICULAR LYMPHOMA: A REPORT FROM THE DANISH LYMPHOMA REGISTRY ON THE TREATMENT APPROACHES AND OUTCOMES IN NEWLY DIAGNOSED PATIENTS

EHA Library, Jelena Jelicic, 4160336

THE PROGNOSTIC VALUE OF CIRCULATING CELL-FREE METHYLATED EBV-DNA IN EXTRANODAL NK/T CELL LYMPHOMA

EHA Library, Jinhua Liang, 4160337

MOLECULAR SUBTYPE-GUIDED TARGETED THERAPY COMBINED WITH R-MINE (R-MINE+X) IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A SINGLE-ARM, OPEN-LABEL, MULTICENTER PHASE II STUDY

EHA Library, Jinhua Liang, 4160338

CAR T-CELL THERAPY IS EFFICIENT IN VITREORETINAL LYMPHOMAS. A LOC NETWORK STUDY.

EHA Library, cecile pivert, 4160342

OVERALL SURVIVAL IMPROVEMENT OF THE R/R DLBCL PATIENT POPULATION TREATED IN THE YEAR 2021 AND BEYOND

EHA Library, Marek Trneny, 4160345

PROGNOSTIC SIGNIFICANCE OF SEQUENTIAL CIRCULATING-TUMOR DNA ASSESSMENTS IN PATIENTS WITH ADVANCED STAGE DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH R-CHOP IMMUNOCHEMOTHERAPY

EHA Library, Ga-Young Song, 4160346

LONG-TERM EFFICACY OF COMPLETE REMISSION PATIENTS WITH R/R DIFFUSE LARGE B-CELL LYMPHOMA AFTER CAR-T THERAPY: BTK INHIBITOR MAINTENANCE TREATMENT MAY PROLONG REMISSION DURATION

EHA Library, Liu Rui, 4160347

IMPACT OF PRE-INFUSION CD19 EXPRESSION ON CAR T-CELL EXPANSION AND CLINICAL OUTCOMES IN R/R -B-CELL LYMPHOMA.

EHA Library, Ilenia De Bernardis, 4160348

EFFICACY AND SAFETY OF POLATUZUMAB VEDOTIN, ZANUBRUTINIB AND RITUXIMAB (POLA-ZR) IN UNTREATED ELDERLY AND FRAIL DLBCL PATIENTS: A PROSPECTIVE PHASE 2 CLINICAL TRIAL

EHA Library, Yuhong Ren, 4160349

CLINICAL OUTCOMES OF NEWLY DIAGNOSED PCNSL TREATED WITH RITUXIMAB-METHOTREXATE-CYTARABINE WITH OR WITHOUT IBRUTINIB: A RETROSPECTIVE STUDY

EHA Library, Wenhua Wang, 4160352

BOOM-BOOM RADIATION PRIOR TO LISOCABTAGENE MARALEUCEL IS FEASIBLE AND CONTRIBUTES TO HIGH COMPLETE RESPONSE RATES FOR AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA

EHA Library, Christopher D'Angelo, 4160353

COMBINING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH CD19/CD22 DUAL-TARGET CAR-T THERAPY: A PROMISING STRATEGY FOR REFRACTORY AND RELAPSED HIGH-RISK B-CELL LYMPHOMA

EHA Library, Xian Zhang, 4160354

REAL-WORLD OUTCOMES OF MITOXANTRONE HYDROCHLORIDE LIPOSOME REGIMEN FOR PERIPHERAL T-CELL LYMPHOMA: A SHORT-TERM EFFICACY AND SAFETY ANALYSIS OF TREATMENT-NAÏVE POPULATION (MOMENT)

EHA Library, Jun Ma, 4160355

A PHASE II STUDY OF DUAL EPIGENETIC MODULATION WITH OBINUTUZUMAB/LIPOSOMAL MITOXANTRONE IN CHEMORESISTANT DLBCL PATIENTS POST-SALVAGE THERAPY

EHA Library, Chang-Ju Qu, 4160359

REAL-WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL): A SYSTEMATIC LITERATURE REVIEW (SLR) AND META-ANALYSIS

EHA Library, Olalekan Oluwole, 4160360

INTRAVENOUS MIDDLE-DOSE METHOTREXATE INCORPORATED INTO R-CHOP PREVENTED CENTRAL NERVOUS SYSTEM RELAPSE IN HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: A SINGLE-CENTER RETROSPECTIVE STUDY

EHA Library, Min Lang, 4160361

TREATMENT OUTCOMES AND PROGNOSTIC FACTORS IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA: MULTICENTER REAL-WORLD DATA OF 166 PATIENTS

EHA Library, Selin Kucukyurt Kaya, 4160364

PHASE 2 NIVO-ALCL STUDY OF NIVOLUMAB FOR RELAPSE/REFRACTORY ALK+ ANAPLASTIC LARGE CELL LYMPHOMA, FOR PATIENTS WITH PROGRESSIVE DISEASE OR AS CONSOLIDATIVE IMMUNOTHERAPY AFTER COMPLETE REMISSION.

EHA Library, Charlotte Rigaud, 4160365

PHASE 2 STUDY OF DZD8586, A NON-COVALENT BBB PENETRANT LYN/BTK DUAL INHIBITOR, AS MONOTHERAPY IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: TAI-SHAN9 TRIAL

EHA Library, lugui qiu, 4160368

PRIMARY EFFICACY AND SAFETY OF FIRST-LINE R-MTO REGIMEN (RITUXIMAB, METHOTREXATE, THIOTEPA, AND ORELABRUTINIB) FOLLOWED BY AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PCNSL

EHA Library, Zengjun Li, 4160372

A NOVEL PROGNOSTIC MODEL FOR PREDICTING DISEASE PROGRESSION AND SURVIVAL IN PRIMARY LARGE B-CELL LYMPHOMA OF IMMUNE-PRIVILEGED SITES

EHA Library, Ganggang Wang, 4160374

REAL-WORLD ANALYSIS OF GLOFITAMAB IN RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

EHA Library, Zhiyong Zeng, 4160375

PERSONALIZED GENETICALLY ADAPTED THERAPY FOR NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA: A SINGLE-CENTER PROSPECTIVE STUDY

EHA Library, Marat Mingalimov, 4160376

SAFETY AND EFFECTIVENESS OF BRENTUXIMAB VEDOTIN IN CHINESE CD30-POSITIVE LYMPHOMA ADULTS: AN INTERIM ANALYSIS FROM BRAVE STUDY

EHA Library, WeiLi Zhao, 4160377

LOW SOCIOECONOMIC STATUS IS ASSOCIATED WITH AN INFERIOR PROGNOSIS IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS DESPITE THE AGE

EHA Library, Milla Elvi Linnea Kuusisto-Jauhiainen, 4160380